US Patent

US11590209 — Use of bremelanotide in patients with controlled hypertension

Method of Use · Assigned to Palatin Technologies Inc · Expires 2041-04-29 · 15y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using bremelanotide in patients with controlled hypertension for the treatment of sexual dysfunction in females.

USPTO Abstract

The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.

Drugs covered by this patent

bremelanotide-acetate (BREMELANOTIDE ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3539`	—	bremelanotide-acetate

Patent Metadata

Patent number: US11590209
Jurisdiction: US
Classification: Method of Use
Expires: 2041-04-29
Drug substance claim: No
Drug product claim: No
Assignee: Palatin Technologies Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.